China: Yunhu Technology closes Series A+ funding

Hangzhou-based mobile medical testing platform Yunhu Technology has secured tens of millions RMB in series A+ financing, led by China Creation Ventures.

Existing backers including Vision+ Capital, Morningside Venture Capital, Cash Capital and BioTrack Capital also joined the round. China Renaissance’s Alpha team is the exclusive financial consultant for this round of financing.

Founded in 2017, Yunhu Technology has developed China’s first internet platform for medical examinations. It has three major product lines: a series of platform-based testing products; a SaaS-based platform which is designed for local medication institution to use; and a third party cold chain logistic to support the efficient delivery of blood/drugs.

“The huge gap between the demand and supply in China’s healthcare resources has been a long term issue,” said Yunhu Technology Xiaobin Chen. “We are aiming to break the gap between the healthcare services quality from the countryside and the cities; therefore, to provide an equal healthcare environment for every family in this country.”

The company has more than 800 employees across its offices in Beijing, Shanghai, and Hangzhou.

It previously raised a pre-Series A round investment from Vision+ Capital and Morningside Venture Capital, and Rmb38 million (US$5.7 million) from BioTrack Capital and Cash Capital in Series A financing.